PD-L1 sends a signal to immune cells not to attack cancer cells, something that allows the latter to multiply quickly. Cancer cells have much larger quantities of this protein than other normal cells ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

The most advanced molecules in its pipeline target the IC proteins CD47, a ligand of signal-regulatory protein-α (SIRPα), and PD-L1, a ligand of programmed cell death protein 1 (PD-1 ...

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely ... treatment arms forward suggests there may be an efficacy signal for the TIM-3 drug, which was acquired by GSK when ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...